Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 29 · below the Ichimoku cloud · RSI 20 (oversold) · MACD below its signal
None of the 29 investors followed here reported a position in AZTR in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a AZTR trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Salva Francisco DChief Executive Officer | — | 4.06M | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.9 | -28.3 | 33.7 | 5.1 | -6.5 | -27.0 | -20.8 | 31.6 | -21.1 | -48.2 | −73.0% | ||
| 2025 | -43.2 | 47.5 | -15.1 | 6.6 | -15.2 | -4.7 | -31.8 | -9.8 | -34.7 | -25.2 | -27.9 | -29.7 | −90.7% |
| 2024 | 30.4 | -78.8 | -19.2 | 7.8 | -15.8 | -50.8 | -71.2 | -19.0 | -15.8 | -8.3 | 5.4 | -18.9 | −98.5% |
| 2023 | 3.6 | -47.2 | -24.6 | 0.0 | -30.7 | -11.5 | −74.7% |
Buy / hold / sell counts
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.